Effect of Diclofenac 0.1% Vs. Nepafenac 0.1% on anterior chamber reaction in post-operative (cataract) cases.

Comparison of the Efficacy of Diclofenac 0.1% and Nepafenac 0.1% on anterior chamber cells in patients Undergoing Cataract Surgery: a Prospective clinical practice trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220607055097N2

Enrollment

Registered

2022-07-05

Start date

2021-01-01

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior chamber reaction inside the eye after cataract surgery. Cystoid macular edema following cataract surgery, unspecified eye

Interventions

Intervention 1: Intervention group: Topical Diclofenac 0.1% eye drops (TD), used 4 times/day for 4 weeks in the operated eyes. Intervention 2: Intervention group: Topical Nepafenac 0.1% (TN) eye drops

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients’ = 50 yrs. Both males and females with visually significant senile-cataracts under-going phacoemulsification with intra-ocular lens implantation

Exclusion criteria

Exclusion criteria: Any past intra-ocular surgery Any history of any intra-ocular inflammatory diseases, Traumatic globe injuries Corneal disorders impairing the view Any glaucomatous diseases of eye Pseudo-exfoliation cataracts any retinal/macular abnormalities, such as macular edema due to other etiologies or epi-retinal membranes or any age-related maculopathy. Those not willing to follow the study protocols and requirements of follow up Those who were pre-diabetics and confirmed diabetics Those with systemic autoimmune/inflammatory disorders or any history of allergic reaction to the study drugs or other NSAIDs Patients with eventful phaco surgery such as posterior-capsular tear, vitreous-prolapse or post-operative fibrinous reactions

Design outcomes

Primary

Measure	Time frame
BCVA (visual acuity) in Log MAR. Timepoint: Baseline, 1st day, 2nd, 4th and 8th week. Method of measurement: VA measured with Snellen chart and than converted into Logarithm of minimum angle of resolution.;Anterior chamber cells. Timepoint: Baseline, 1st day, 2nd, 4th and 8th week. Method of measurement: Slit lamp examination method by counting the no. of cells in anterior chamber of eye.;Central macular thickness. Timepoint: Baseline, 1st day, 2nd, 4th and 8th week. Method of measurement: Central macular thickness was measured in microns by SD-OCT.	—

Measure

Time frame

BCVA (visual acuity) in Log MAR. Timepoint: Baseline, 1st day, 2nd, 4th and 8th week. Method of measurement: VA measured with Snellen chart and than converted into Logarithm of minimum angle of resolution.;Anterior chamber cells. Timepoint: Baseline, 1st day, 2nd, 4th and 8th week. Method of measurement: Slit lamp examination method by counting the no. of cells in anterior chamber of eye.;Central macular thickness. Timepoint: Baseline, 1st day, 2nd, 4th and 8th week. Method of measurement: Central macular thickness was measured in microns by SD-OCT.

—

Countries

Pakistan

Contacts

Public ContactAdnan Ahmad

Nowshera Medical College, Nowshera

dradnanahmad@hotmail.com+92 91 2586506

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026